Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nexalin Technology, Inc. (NXL : NSDQ)

• Company Description    Nexalin Technology Inc. designs and develops neurostimulation products for mental health epidemic. It licenses and markets Nexalin Device, a non-invasive and drug-free therapy for the treatment of anxiety and insomnia. Nexalin Technology Inc. is based in Houston, Texas. Number of Employees: 6

• Price / Volume Information    Yesterday's Closing Price: $1.27 Daily Weekly Monthly 20 Day Moving Average: 128,164 shares Shares Outstanding: 13.33 (millions) Market Capitalization: $16.93 (millions) Beta: 4.67 52 Week High: $4.49 52 Week Low: $0.53 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.35% -34.95% 12 Week -61.63% -58.55% Year To Date -53.99% -52.18%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1776 YORKTOWN SUITE 550 - Houston,TX 77056 USA ph: 832-260-0222 fax: - nxl@crescendo-ir.com http://www.nexalin.com

• General Corporate Information    Officers Mark White - Chief Executive Officer and Chief Financial Office Carolyn Shelton - Senior Vice President of Quality; Clinical and Reg Alan Kazden - Director Ben Hu - Director Leslie Bernhard - Director Peer Information Nexalin Technology, Inc. (EVOL) Nexalin Technology, Inc. (RAMP) Nexalin Technology, Inc. (LGTY) Nexalin Technology, Inc. (ALOT) Nexalin Technology, Inc. (CXT) Nexalin Technology, Inc. (TGHI) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: Technology Services Sector: Business Services CUSIP: 65345B201 SIC: 3845 Fiscal Year Fiscal Year End: December Last Reported Quarter: 12/01/24 Next Expected EPS Date: 05/09/25 Share - Related Items Shares Outstanding: 13.33 Most Recent Split Date: (:1) Beta: 4.67 Market Capitalization: $16.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/09/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.60 Price/Cash Flow: - Price / Sales: 100.16 EPS Growth vs. Year Ago Period: -180.00% vs. Previous Quarter: -21.74% Sales Growth vs. Year Ago Period: 28.57% vs. Previous Quarter: -25.00% ROE 03/31/25 - - 12/31/24 - -247.11 09/30/24 - -187.59 ROA 03/31/25 - - 12/31/24 - -219.24 09/30/24 - -167.21 Current Ratio 03/31/25 - - 12/31/24 - 7.24 09/30/24 - 16.42 Quick Ratio 03/31/25 - - 12/31/24 - 6.92 09/30/24 - 15.89 Operating Margin 03/31/25 - - 12/31/24 - -4,500.59 09/30/24 - -3,407.36 Net Margin 03/31/25 - - 12/31/24 - -4,501.18 09/30/24 - -3,407.98 Pre-Tax Margin 03/31/25 - - 12/31/24 - -4,511.59 09/30/24 - -3,418.41 Book Value 03/31/25 - - 12/31/24 - 0.28 09/30/24 - 0.47 Inventory Turnover 03/31/25 - - 12/31/24 - 0.23 09/30/24 - 0.22 Debt-to-Equity 03/31/25 - - 12/31/24 - 0.00 09/30/24 - 0.00 Debt-to-Capital 03/31/25 - - 12/31/24 - 0.00 09/30/24 - 0.00

Powered by Zacks Investment Research ©